Lab21 secures additional IP for Hepatitis C diagnostics


Lab 21 announced that it has completed an agreement to exclusively license the hepatitis C (HCV) diagnostic technology and associated patent applications of Dr. Carol Holland (TROY, MI, USA). The deal was brokered by UTEK-EKMS (CAMBRIDGE, MA, USA), a leading intellectual property (IP) management firm, on behalf of Dr. Holland.

"Lab 21 is committed to providing advanced healthcare testing services and licensing Dr. Holland's technology will allow us to further our development in the area of HCV testing." said Berwyn Clarke, Chief Scientific Officer of Lab 21. He continued: "HCV is a virus that is likely to resemble HIV in that antiviral drug resistance will become a significant issue as and when new small molecule drugs are licensed. The acquisition of this technology is a powerful tool in support of our commitment to develop resistance genotyping assays that will allow optimal clinical management of HCV patients."

The details and terms of the agreement were not disclosed.

Other news from the department research and development

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics